Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response

  • Fate Therapeutics Inc FATE revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma.
  • At the 2021 American Society of Clinical Oncology Meeting, the Company highlighted positive interim FT516 program data for 11 pretreated patients.
  • Related: Fate Therapeutics Shares Positive B-Cell Lymphoma Data at ASCO21.
  • At a three-month check-in, eight of 11 B cell lymphoma patients who received FT516 reported an objective response with no major safety signals. 
  • But at a July 7 cutoff, just five patients (45%) maintained those responses, with two complete responders seeing their disease progress and a partial responder forced to receive an “additional anti-cancer therapy.”
  • FT516’s results in patients with prior CD19 CAR-T therapy, two of four posted a complete response, spurring Fate to announce a dose-expansion cohort in that population.
  • Meanwhile, FT596 posted early data of its showing promising efficacy.
  • Interim data showed that 10 of 14 patients across two dose-escalation cohorts posted an objective response, including seven complete responders, including two of three patients treated with a combo of FT596 and Rituxan after autologous CD19 CAR-T therapy.
  • Fate expects to present further data from both studies at the upcoming ASH conference in December, including a first look at the durability of response for FT596.
  • Price Action: FATE shares closed 5.90% lower at $85.63 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefslymphomaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!